N-乙基-1-甲基-1H-苯并咪唑-2-胺 | 98711-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N-乙基-1-甲基-1H-苯并咪唑-2-胺
• 英文名称: 2-ethylamino-1-methylbenzimidazole
• 英文别名: N-ethyl-1-methyl-1H-benzo[d]imidazol-2-amine；N-ethyl-1-methylbenzimidazol-2-amine
• CAS: 98711-68-3
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.233
• InChiKey: WOZJNZYOXWVNOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(4H-1,2,4-三唑-4-基)-1H-苯并咪唑 以 二氯甲烷 为溶剂， 反应 24.25h， 生成 N-乙基-1-甲基-1H-苯并咪唑-2-胺
  参考文献：
  名称：

  Castellanos, Maria Luisa; Llinas, Montserrat; Bruix, Marta, Journal of the Chemical Society. Perkin transactions I, 1985, p. 1209 - 1216

  摘要：

  DOI：

文献信息

• Microwave assisted one pot synthesis of 2-ethylamino benzimidazole, benzoxazole and benzothiazole derivatives
  作者：Thirupathi Rapolu、Pavan Kumar K. V. P.、Korupolu Raghu Babu、Satheesh Kumar Dende、Rajashekar Reddy Nimmareddy、Leleti Krishnakanth Reddy

  DOI：10.1080/00397911.2019.1599952

  日期：2019.5.19

  rapid and efficient one-pot method for the synthesis of 2-ethylamino benzimidazole, benzoxazole, and benzothiazole derivatives has been described. The reaction of o-phenylenediamines or o-aminophenols or 2-mercaptoanilines with EDC.HCl under microwave irradiation afforded the corresponding 2-ethylamino benzimidazole, benzoxazole and benzothiazole derivatives in excellent yields. Graphical Abstract

  摘要 描述了一种快速高效的一锅法合成 2-乙氨基苯并咪唑、苯并恶唑和苯并噻唑衍生物。邻苯二胺或邻氨基苯酚或 2-巯基苯胺与 EDC.HCl 在微波辐射下的反应以优异的产率得到相应的 2-乙氨基苯并咪唑、苯并恶唑和苯并噻唑衍生物。图形概要
• [EN] IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE PRÉSENTANT DES PROPRIÉTÉS ANTAGONISTES DU A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2019118313A1

  公开（公告）日：2019-06-20

  Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  本文披露了具有Formula I结构的化合物，或者其任何药学上可接受的盐：其中：“Z”和R1在此有定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度发现的受体。据信，这些化合物和药物配方在治疗或管理神经退行性疾病，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍方面是有用的。
• 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20080125399A1

  公开（公告）日：2008-05-29

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR）。这些化合物有助于增强肌肉张力减弱和治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病，包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、老化皮肤、男性性腺功能减退、女性绝经后症状、动脉硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、良性前列腺增生症（BPH）、癌症消耗综合征、阿尔茨海默病、肌营养不良、认知能力下降、性功能障碍、睡眠呼吸暂停、抑郁症、早发性卵巢衰竭和自身免疫性疾病，可单独使用或与其他活性剂联合使用。
• Receptor Function Regulating Agent
  申请人：Itoh Fumio

  公开号：US20080021069A1

  公开（公告）日：2008-01-24

  The present invention relates to a GPR40 receptor function regulator comprising a fused imidazole compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof. The GPR40 receptor function regulator is useful as an agent for the prophylaxis or treatment of obesity, hyperinsulinemia, type 2 diabetes and the like.

  本发明涉及一种GPR40受体功能调节剂，其包括由下式表示的融合咪唑化合物：其中每个符号如规范所定义，或其盐或前药。该GPR40受体功能调节剂可用作预防或治疗肥胖症、高胰岛素血症、2型糖尿病等药物。
• CASTELLANOS, M. L.;LLINAS, M.;BRUIX, M.;MENDOZA, J. DE;MARTIN, M. R., J. CHEM. SOC. PERKIN TRANS., 1985, N 6, 1209-1215
  作者：CASTELLANOS, M. L.、LLINAS, M.、BRUIX, M.、MENDOZA, J. DE、MARTIN, M. R.

  DOI：——

  日期：——